PT  - JOURNAL ARTICLE
AU  - Ling Li
AU  - Jiaying Lu
AU  - Ming Li
AU  - Sun Yimin
AU  - Xiuming Li
AU  - Yihui Guan
AU  - Jian Wang
AU  - Chuantao Zuo
TI  - <strong>Binding Characteristics of the New-Generation Tau PET Tracer [18F] -APN-1607 in Progressive Supranuclear Palsy</strong>
DP  - 2020 May 01
TA  - Journal of Nuclear Medicine
PG  - 461--461
VI  - 61
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/61/supplement_1/461.short
4100  - http://jnm.snmjournals.org/content/61/supplement_1/461.full
SO  - J Nucl Med2020 May 01; 61
AB  - 461Background: Progressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder characterized by tau pathology in neurons and glial cells. As the next generation PET imaging agent, [18F]-APN-1607 ([18F]-PM-PBB3) was designed for capturing pathological tau aggregates in diverse neurodegenerative disorders. This work explored the usefulness of [18F]-APN-1607 in assessing characteristic distributions of tau pathologies and their association with clinical symptoms of living progressive supranuclear palsy (PSP) patients. METHODS: We assessed 18 PSP patients and 10 age-matched healthy control subjects. Both cohorts underwent clinical scoring, MR scans, and [18F]-APN-1607 PET/CT scans. The tosylate precursor used for the synthesis of [18F]-APN-1607 was provided by APRINOIA Therapeutics (Suzhou, China) and the synthesis was prepared in Huashan hospital (Shanghai, China). PET images were spatially normalized to Montreal Neurological Institute template space. Standard uptake value ratios (SUVRs) were calculated using AAL3 (Automated Anatomical Labeling atlas) volumes of interest (VOIs). All VOIs were referenced to a subsection of cerebellar gray matter (cere-crus) as well as a parametrically derived white matter-based reference region (parametric estimate of reference signal intensity [PERSI]). T test and correlation analyses were used to explore its performance. RESULTS: There were significant differences in binding potential for [18F]-APN-1607 between PSP patients and healthy control subjects. PSP patients exhibited greater radioligand retention than healthy control subjects in multiple brain regions, including occipital lobe (0.991±0.038), caudate (0.832±0.078), putamen(1.271±0.152), pallidum (1.561±0.171), raphe nucleus(1.683±0.312), and substantia nigra (1.355±0.186). Conclusions: This study demonstrated significant uptake discrimination of [18F]-APN-1607 between PSP and HC subjects in occipital lobe, caudate, putamen, pallidum, raphe nucleus, and substantia nigra, which may reflect neuropathology. We are recruiting more patients in a follow-up study to explore association between measures of tau pathology and clinical assessment in PSP cohort.